Medtronic PLC has launched clinical trial programs for two of its next-generation drug-eluting stents, Resolute Onyx and its earlier-stage drug-filled stent device.
For the zotarolimus-eluting Resolute Onyx stent, the firm is launching a U.S. pivotal study in the U.S. following a November 2014 CE mark of the device. The U.S. trial will...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?